Company-reported prevalence
Duravyu
Overview
| Field | Value |
|---|---|
| Drug | Duravyu (vorolanib intravitreal insert and EYP-1901) |
| Indication | Wet age-related macular degeneration |
| Disease | Wet AMD (wet age-related macular degeneration); later stages of AMD for the projection statement |
| Company | EyePoint, Inc. (developer; licensee of vorolanib for ophthalmology indications worldwide except China, Hong Kong, Taiwan, and Macau); Equinox Science, LLC (licensor; retains China, Hong Kong, Taiwan, and Macau) |
| Documents searched | EyePoint website home, programs, about, and science and technology pages (accessed October 2026); EyePoint press releases filed as Form 8-K exhibits dated March 2023, December 2023, October 2024, December 2024, May 2025, July 2025, November 2025, May 2026, August 5, 2026, and August 17, 2026; Form 10-K for 2024 (March 2025); Form 10-K for 2025 (March 2026); Form 10-Q for the quarter ended June 30, 2026 (August 2026); investor and corporate presentations filed as Form 8-K exhibits (July 2022, December 2023, January 2024, June 2024, August 2026); LUGANO topline results presentation (August 2026); LUGANO expanded results presentation (September 2026); scientific congress presentations and posters posted on the EyePoint website (2024 to 2026); no public document from Equinox Science was identified |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Number affected (later stages of AMD): EyePoint Form 10-K for 2025, March 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Prevalence (share of all AMD): EyePoint Form 10-K for 2025, March 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Europe
No evidence found.
Global
No evidence found.
Other countries and regions
No evidence found.
Geography not stated
No evidence found.
Sources the company cites
No evidence found.